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Background: Diffuse optical spectroscopy (DOS) has been demonstrated capable of monitoring response to neoadjuvant
chemotherapy (NAC) in locally advanced breast cancer (LABC) patients. In this study, we evaluate texture features of pretreatment
DOS functional maps for predicting LABC response to NAC.
Methods: Locally advanced breast cancer patients (n¼ 37) underwent DOS breast imaging before starting NAC. Breast tissue
parametric maps were constructed and texture analyses were performed based on grey-level co-occurrence matrices for feature
extraction. Ground truth labels as responders (R) or non-responders (NR) were assigned to patients based on Miller–Payne
pathological response criteria. The capability of DOS textural features computed on volumetric tumour data before the start of
treatment (i.e., ‘pretreatment’) to predict patient responses to NAC was evaluated using a leave-one-out validation scheme at
subject level. Data were analysed using a logistic regression, naive Bayes, and k-nearest neighbour classifiers.
Results: Data indicated that textural characteristics of pretreatment DOS parametric maps can differentiate between treatment
response outcomes. The HbO2 homogeneity resulted in the highest accuracy among univariate parameters in predicting response
to chemotherapy: sensitivity (%Sn) and specificity (%Sp) were 86.5% and 89.0%, respectively, and accuracy was 87.8%. The highest
predictors using multivariate (binary) combination features were the Hb-contrastþHbO2-homogeneity, which resulted in a %Sn/
%Sp¼ 78.0/81.0% and an accuracy of 79.5%.
Conclusions: This study demonstrated that the pretreatment DOS texture features can predict breast cancer response to NAC
and potentially guide treatments.
*Correspondence: Dr GJ Czarnota; E-mail: gregory.czarnota@sunnybrook.ca
Received 7 March 2017; revised 16 March 2017; accepted 17 March 2017
r 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
FULL PAPER
Keywords: diffuse optical spectroscopy imaging; breast cancer; imaging biomarkers
British Journal of Cancer (2017), 1–11 | doi: 10.1038/bjc.2017.97
www.bjcancer.com |DOI:10.1038/bjc.2017.97 1Advance Online Publication: 13 April 2017
Breast cancer is the second leading cause of cancer-related
mortality in women, and accounts for approximately one-third
of new malignancies (Desantis et al, 2014). Nearly 20% of cases
present as locally advanced breast cancer (LABC), which are
characterised as stage IIB or stage III disease; thus, having large/
bulky tumours which are often 45 cm in size and involving the
lymph nodes or skin (Giordano, 2003; Whitman and Strom, 2009).
Survival outcomes for LABC are poor; only 50% of patients survive
beyond 5 years (Lee and Newman, 2007). Guidelines from the
National Institute for Health and Care Excellence (NICE) in the
United Kingdom recommend neoadjuvant chemotherapy (NAC)
for clinical management to downstage tumours prior to locor-
egional treatment with surgery and radiotherapy (Cance et al,
2002; Lee and Newman, 2007; National Institute For Health And
Clinical Excellence (NICE), 2009). However, variable tumour
responses have been shown in patients receiving NAC and there is
evidence to suggest that favourable response to NAC correlates to
improved disease-free survival (DFS) (Mathew et al, 2009; von
Minckwitz et al, 2012).
Measuring tumour response at early stages of NAC may help
guide treatments for potentially improved DFS. Standard methods
use clinical palpation or medical imaging such as magnetic
resonance imaging (MRI) to measure anatomical changes
(Eisenhauer et al, 2009). However major limitations include
variability in reader expertise, image reproducibility, and the time
delay between biological and anatomical changes (Eisenhauer et al,
2009; Roblyer et al, 2011). Thus, emerging studies are investigating
quantitative imaging methods to evaluate tumour response based
on functional and biological tumour alterations to NAC within
days to weeks after treatment initiation (Jakubowski et al, 2004;
Roblyer et al, 2011). Recent studies have indicated that diffuse
optical spectroscopy (DOS) imaging can characterise tumour
response by focusing on changes in tissue composition (Cerussi
et al, 2007; Roblyer et al, 2011; Jiang et al, 2014). Maps of tumour
physiological features, such as haemoglobin are computed from
tissue optical properties that are based on near-infrared optical
scattering and absorption (Cerussi et al, 2006). For breast tissue,
significant optical absorbers include oxy-haemoglobin (HbO2),
deoxy-haemoglobin (Hb), water (H2O), and lipids (Li) (Cerussi
et al, 2006). Their concentrations can be estimated by measuring
the absorption coefficient (ma) and using Beer’s law
equation (Cerussi et al, 2011). Also, tissue optical parameters such
as the reduced scattering coefficient (m0s) can provide additional
information on tissue microstructure (B0.2mm), corresponding to
optical scattering effects from mitochondria and the cell nucleus
(Mourant et al, 2000; Cerussi et al, 2006). In previous studies,
changes in DOS markers such as HbO2 have been correlated to
tumour response within 1 week of starting NAC (Roblyer et al,
2011) and after several cycles of chemotherapy (Schaafsma et al,
2015). A study by Ueda et al (2012) also measured baseline tumour
oxygen saturation (StO2) prior to NAC and reported significantly
higher StO2 in tumours that demonstrated pathological complete
response (pCR) vs non-pCR.
Second-order statistical analysis of DOS parametric images can
also yield texture features and aid in discriminating tumour
response during NAC (Sadeghi-Naini et al, 2015). Feature
extraction methods such as those based on grey-level co-
occurrence matrices (GLCM) can be applied to compute the
probabilities of relative pixel intensities of images from the spatial
distribution of their voxels (Haralick et al, 1973). Grey-level co-
occurrence matrices texture features include contrast (con),
correlation (cor), homogeneity (hom), and energy (ene), and are
dependent on the number of grey-levels (Ng) in the image or
within the region of interest (ROI). Such techniques have been
applied to several modalities, such as X-ray mammography (Li
et al, 2005), MRI (Lerski et al, 1993; Chen et al, 2007), positron-
emission tomography (Chicklore et al, 2013), and ultrasound
(Yang et al, 2012) in order to discriminate and characterise tissue
types (Castellano et al, 2004). In breast studies, GLCM analysis has
been able to classify benign and malignant lesions using planar
(2D) and volumetric (3D) MRI images (Gibbs and Turnbull, 2003;
Chen et al, 2007). For X-ray mammography, GLCM analysis has
been used to segment lesion borders of stellate (malignant) breast
masses (Gupta and Undrill, 1995). It was also recently reported
that texture-based features from quantitative ultrasound imaging
can be used to classify responders and non-responders early during
NAC treatment (Sadeghi-Naini et al, 2014). These previous
findings suggested that textural features may detect the acute,
heterogeneous microstructural features carried in the parametric
layout (Sadeghi-Naini et al, 2014). The research here is built on
those previous findings but focusses on the pretreatment DOS
texture features of the tumour area in 37 patients with LABC.
The aims of the present study were to carry out baseline DOS
texture analysis to characterise pretreatment tumour heterogeneity
as a marker for NAC response. Diffuse optical spectroscopy breast
maps were acquired in LABC before treatment and here, texture
features were used to predict treatment response (responder vs
non-responder) based on three classifier models: a logistic
regression analysis, naive Bayes, and k-nearest neighbour
(k-NN)). The classification ground truth was based on final
Miller–Payne (MP) pathologic response criteria. The results of this
study demonstrate a significant difference (Po0.05) in the DOS
textural features between response groups for features such as the
Hb-hom and StO2-con. The results indicate that textural
characteristics of pretreatment DOS parametric maps can serve
as predictors of pathological response to NAC. Diffuse optical
spectroscopy imaging biomarkers could potentially help guide
treatment for improved treatment outcomes in LABC patients, and
for tailoring personalised treatment.
MATERIALS AND METHODS
Patient treatment and response criteria. This study was
approved by the institutional research ethics board at Sunnybrook
Health Sciences Centre, Toronto, Canada and all patients signed a
written informed consent before participating in the study. Patients
(n¼ 37) were included following a biopsy-confirmed diagnosis of
LABC, aged 18–85, and were recommended for NAC. As part of
the patient’s standard of care, tumour molecular and histological
features such as: oestrogen receptor (ER) status, progesterone
receptor (PR) status, and human epidermal growth factor receptor
amplification (Her2/Neu) were determined during the patient’s
diagnostic work-up. Patients had pretreatment MRI for initial size
measurements. Clinical data were recorded in the patient’s
electronic medical record and retrieved for this study.
Neoadjuvant chemotherapy consisted of combination anthracy-
cline- and taxane-based therapy for 6–8 cycles. These included
combination therapies of either AC-T (Adriamycin, Cyclopho-
sphamide, Taxol) or FEC-D (Fluorouracil, Epirubicin, Cyclopho-
sphamide, Docetaxel). For Her2/Neu-amplified tumours, patients
also received Trastuzumab concurrently with taxanes. Patients
were clinically assessed by physical examination for the duration of
treatment by their medical oncologist. Patients were assessed for
NAC response pathologically using MP criteria (Ogston et al, 2003;
Provenzano et al, 2015). MP criteria is a five-point grading system
where MP-5 indicates no malignant cells identified in the tumour
bed after treatment; MP-4 indicates a significant disappearance of
tumour cells (490% loss of tumour cells); MP-3 indicates a
30–90% disappearance of tumour cells; and MP-2 and MP-1
indicate no change or minor loss (o30%) of tumour cells (Ogston
et al, 2003). Patients were considered responders (R) if there was at
least a 30% reduction in tumour cells under microscopy (i.e., MP
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3–5) (Ogston et al, 2003). Patients were otherwise classified as non-
responders (NR) (MP 1–2). On the basis of these criteria, 27
patients were classified as responders and 10 patients were non-
responders; that is, the ratio of responders to non-responders was
B3. This labelling was used as the ground truth in the classifiers
analyses performed as explained in the next subsections.
Tomographic diffuse optical spectroscopy imaging. Time-
domain DOS imaging was performed on the patient’s breast prior
to the start of NAC, using a commercially developed tomographic
DOS imaging device (SoftScan, Montreal, QC, Canada). Patients
were laid prone with the breast positioned inside an imaging
chamber. The breast was stabilised with compression plates in the
craniocaudal direction and optical compensation medium was
added for optical coupling between surfaces (ma¼ 0.04 cm
 1;
ms¼ 11 cm
 1 (Intes, 2005)). Near-infrared light transmission was
carried out using four individually pulsed semiconductor diode
lasers operating at 690, 730, 780, and 830 nm, with a pulse duration
ofo150 ps, 20MHz repetition frequency, and an average power of
0.5mW (PicoQuant, Berlin, Germany). Optical detection used five
output-fibered collimators that collected photons transmitted
through the breast. Fibered collimators were coupled to photo-
multiplier tubes (Hamamatsu, Bridgewater, NJ, USA) and directed
to a photon counting module (Becker & Hickl, Berlin, Germany).
The temporal-point spread function was measured and used to
compute the absorption (ma) and scattering (ms) coefficients based
on photon diffusion theory in tissue (Xu and Povoski, 2007).
Parametric data included measurements of dominant DOS
chromophores in breast comprising of HbO2 and Hb (Cerussi et al,
2006). The absorbance spectra of these tissue components were
used to determine their concentrations (C) using the Beer–Lambert
law, with known molar extinction coefficients (e) (Equation 1):
ma ¼ eC ð1Þ
Other DOS parameters, such as %water, %lipid, scattering power
(b), and scattering amplitude (A) were measured using the power-
law fit of the scattering spectra within a given wavelength (l)
(Equation 2). This relationship is based on a Mie scattering
approximation (Tromberg et al, 2005):
msðlÞ ¼ Al
b ð2Þ
Additionally, other optical parameters such as StO2, oxygen
desaturation (St), total haemoglobin (HbT), and the tissue optical
index (TOI) were calculated from the Hb, HbO2, %water, and
%lipid, and these calculations have been described elsewhere (Intes,
2005; Cerussi et al, 2011).
DOS texture analysis. Whole-breast tomographic DOS para-
metric maps were constructed with an in-plane resolution of
3 3mm2 and slice thickness of 7.5mm. The ROI was an ellipsoid
contour that was manually annotated around the tumour (Review
Workstation, SoftScan; Schaafsma et al, 2015). Tumour ROIs were
also selected with reference to the patients’ pretreatment MRI with
breast radiologists (BC, SGB, RFR).
Grey-level co-occurrence matrices texture analysis was per-
formed on tomographic DOS data for the entire tumour volume
and averaged over multiple frames; corresponding to the DOS
parameters. A bilinear interpolation was applied to compensate for
differences in the spatial resolutions, thus obtaining volumetric
images with isotropic voxels (3 3 3mm3; Sadeghi-Naini et al,
2015). For the GLCM, grey-tone intensities (Ng) were quantised
into 16 grey-levels from the DOS parametric maps. A symmetric
GLCM was constructed based on the spatial relationship of each
voxel’s neighbours using a displacement vector; the magnitude of
the displacement vector was one to four voxel distances. A
cumulative GLCM was calculated in 13 directions (451 rotations in
each adjacent direction) relative to the central voxel (Chen et al,
2007). The resulting co-occurrence features included: energy,
homogeneity, contrast, and correlation. These were previously
defined by (Haralick et al (1973)):
Energy ðEneÞ ¼
XNg
i¼1
XNg
j¼1
g 2ij ð3Þ
where the energy (angular second moment) describes the textural
uniformity of the image, 0pEnep1, and gij is the ith and jth entry
of the GLCM representing a grey-tone intensity in the matrix;
Homogeneity Homð Þ ¼
XNg
i¼1
XNg
j¼1
1
1þ i jð Þ2
gij ð4Þ
where the homogeneity (inverse difference moment) measures the
diagonal elements within the displacement vector of the GLCM
and relates the similarities in grey tones between voxels;
Contrast Conð Þ ¼
XNg
i¼1
XNg
j¼1
i jð Þ2gij ð5Þ
where the contrast measures the differences between the lowest and
highest voxels’ grey tones and finally;
Correlation Corð Þ ¼
PNg
i¼1
PNg
j¼1 ijð Þg mxmy
sxsy
ð6Þ
where the correlation measures the linear dependency on
neighbouring grey-tone intensities; and sx, sy are the s.d., and
mx, my are the means of the probability matrix. Therefore, a total of
40 DOS texture features was included for analysis; there were 10
DOS parameters comprised of four GLCM features for each
parameter (Supplementary Figure 1). Diffuse optical spectroscopy
texture features were calculated using MatLab R2011b (The
MathWorks Inc., Natick, MA, USA).
Statistical analysis and classification. All statistical analyses were
performed using SPSS V.22 (IBM Corp., Armonk, NY, USA) and
MatLab R2011b (The MathWorks Inc.). The DOS–GLCM features
were compared for significant differences between R and NR
patients (n¼ 37). Additionally, a subgroup analysis was completed
based on tumour molecular features and chemotherapy treatments.
The subgroups included ERþ (n¼ 27), ‘triple-negative’ (ER /
PR /HER2 ; n¼ 7), FEC-D (n¼ 16) and AC-T (n¼ 21)
chemotherapy. HER2þ patients were not considered due to the
limited number of non-responders in this subgroup (n¼ 2). For
the classifiers to be used, at least three subjects are needed within
each response group to perform the leave-one-subject-out valida-
tion scheme; as it may happen that one subject be in the test set,
one in the validation set, and therefore, one additional subject is
needed in the training set.
Comparisons were first tested for normality violations using a
Shapiro–Wilk test. Normally distributed parameters were tested for
significance using an unpaired t-test (two-sided within the 95%
confidence interval). Otherwise, a Mann–Whitney test was
performed (two-sided, 95% confidence).
In this study, a logistic regression analysis, a naive Bayes
classification method, and a k-NN classifier were used to analyse
the predictive value of DOS–GLCM features. A naive Bayes
classification method assumes that features are independent of
each other within the class variable. The k-NN classifier considers a
test point and analyses the neighbouring points to form a class
based on the frequency and distance between points. Four
performance measures including the sensitivity (%Sn), specificity
(%Sp), accuracy, and area under curve (AUC) of the receiver-
operating characteristic (ROC) were calculated for both univariate
parameters and multivariate parameters. These measures were
used to compare the performance of the three classifiers. Prior to
training and test validation, the data set was randomly subsampled
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into 20 subsets with replacement. Each subset had equal numbers of
responders and non-responders; this method was used to account for
the data imbalance between the two response groups. Since each
patient was represented using 40 DOS–GLCM features, and due to a
limited sample size, in order to prevent the ‘curse of dimensionality’
(Jain et al, 2000), a feature selection based on sequential forward
selection (SFS) algorithm in a wrapper framework (Duda et al, 2001)
was performed to find the best (in the univariate case) or at most two
(in the multivariate case) features. In order to prevent the peaking
phenomenon due to the curse of dimensionality (Jain et al, 2000), the
number of features should be at most 1/10th of the number of data
samples, and since in the balanced data, there were only 20 data
samples, a maximum of two features were selected for multivariate
analysis using the SFS algorithm. The classifiers were evaluated using
a leave-one-out cross validation at subject level. At each fold, the test
set (one patient) remained unseen during the feature selection,
tuning, and training of a classifier. Furthermore, at each fold, a leave-
one-out cross validation was performed on the training set for the
purpose of feature selection and tuning a classifier parameter (such as
k in k-NN). Thus, at each fold, the training set was further divided
into training and validation sets. The most discriminative feature(s)
and the optimal classifier parameter were selected on the training set
at each fold without involving the left-out test sample. Subsequently
at each fold, the classifier was trained on the whole-training set using
the optimal classifier parameter and selected features, and tested on
the test sample. This process was repeated on all samples (in the
leave-one-out process) to evaluate the performance of the classifier.
In order to test if there was a correlation between DOS–GLCM
features and tumour biology and clinical features, a multiple linear
regression analysis was completed using methods previously reported
for imaging biomarker analysis (Evans et al, 2013). The following
clinical variables were considered in the model: Patient’s age, ER/PR
status, Her2 status, tumour size, and pathologic response. The
regression coefficient (r) was calculated between the clinical variables
and DOS–GLCM features. A statistical test of significance was also
performed using an ANOVA test with an alpha of 0.05.
RESULTS
Patient characteristics. This study included n¼ 37 patients with
biopsy-confirmed LABC. The median age of subjects was 50 years
old. The mean tumour size in the largest dimension prior to NAC
was 5.4 cm for responders and 7.0 cm for non-responders. The
molecular features of tumours indicated that 27 patients were ER/
PR positive. A total of 12 patients were Her2/Neu positive. A total
of n1¼ 27 patients were classified as responders and n2¼ 10
patients as non-responders based on the ultimate pathological data
(described below). All patients received taxane- and anthracycline-
based chemotherapies: 21 patients received AC-T chemotherapy
and 16 patients underwent FEC-D chemotherapy. Twelve patients
who were Her2/Neu positive received Trastuzumab during taxane
chemotherapy. Patient characteristics are summarised in Table 1.
Representative DOS parametric maps for responders and non-
responders, and the pretreatment MRI are shown in Figure 1.
Tumour haemoglobin and oxygenation – texture features
demonstrate significant differences between response groups.
Box-and-whisker plots for DOS–GLCM haemoglobin and StO2
features are presented in Figures 2 and 3, respectively. The deoxy-
haemoglobin-homogeneity (Hb-hom) feature demonstrated a
significant difference between responders and non-responders;
(P¼ 0.030). The Hb-hom feature was greater in NR compared to R
(mean value: 0.329±0.06 (a.u.) (±s.d.) vs 0.282±0.06, respec-
tively). However, other features such as the Hb-con did not
demonstrate a significant difference between groups (P¼ 0.066)
(Figure 2). For the HbO2-GLCM features, the HbO2-cor was
greater for responders (R¼ 0.205±0.06 (a.u.) compared to
NR¼ 0.156±0.05 (a.u.) (mean values), Po0.024). The HbT
measurements in tumours demonstrated significant differences in
homogeneity (HbT-hom) (P¼ 0.047). Other features were not
significantly different such as the HbO2-con (P¼ 0.058) and
HbO2-hom (P¼ 0.088).
There were also significant differences between response groups
in tumour oxygenation texture features (St-con and StO2-con,
Po0.05). The St-con was significantly different between response
groups (P¼ 0.044); while other features such as St-hom were close
to being significantly different (P¼ 0.058). St-con measurements
were greater in responders (mean value: 21.87±2.70 (a.u.)) vs non-
responders (mean value¼ 20.43±1.41 (a.u.)) (Po0.05). Conver-
sely the StO2-con parameter was greater in non-responders (mean
value¼ 22.13±2.63 (a.u.)) compared to responders (mean
value¼ 19.87±3.02 (a.u.)) (Po0.05).
Diffuse optical spectroscopy texture features that were sig-
nificantly different between response groups (N vs NR) were
analysed using the classifier models (Table 2A). In general, naive
Bayes classification performed the best among the classifier models
used in this study. For the HbT-hom, naive Bayes classification
resulted in a %Sn of 84%, and %Sn of 85% (AUC¼ 0.813), in
comparison to k-NN classification, which resulted in a classifica-
tion of only %Sn¼ 74%, %Sp¼ 47%, and AUC of 0.552
(Table 2A). Analysis of all DOS texture features was also
performed, independent of statistical significance between groups,
using the three classifiers (logistic regression analysis, the naive
Bayes model, or k-NN classifier). However, Table 2B presents the
best DOS texture features from all possible univariate features
(d¼ 40) extracted from each classifier model. The corresponding
ROC curves with AUCs are presented in Figure 4. Classification
results from significant univariate texture features indicated an
AUC range between 0.756 and 0.821 (Figure 4). A maximum AUC
was observed for HbO2-hom (AUC¼ 0.821) using a naive Bayes
model. Cross validated %Sn and %Sp were 86.5%, and 89.0%,
respectively, and corresponded to an accuracy of 87.8% (Table 2B).
Table 1. Patient and clinical characteristics
Patient and tumour characteristics
n¼37 (All
subjects)
Patients
Age (years) 50
Pretreatment tumour size (MRI, cm)
Responders 5.4
Non-responders 7.0
Molecular and histological features
ERþ 27
Triple negative/basal-like 7
HER2þ 12
Invasive ductal carcinoma 36
Invasive lobular carcinoma 1
Treatment response classification
Responders 27
Non-responders 10
Chemotherapy and targeted therapies
AC-T 21
FEC-D 16
Trastuzumab 12
Abbreviations: AC-T¼ adriamycin, cyclophosphamide, taxol; ER, oestrogen receptor;
FEC-D¼ fluorouracil, epirubicin, cyclophosphamide, docetaxel; MRI, magnetic resonance
imaging. Patients included in the study were diagnosed with biopsy-confirmed locally
advanced breast cancer, and received a combination of anthracycline and taxane-based
chemotherapies following standard institutional guidelines.
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Other classifiers demonstrated a %Sn range between 70.0 and
81.0%, and a Sp of 70.0–73.0%. This corresponded to an accuracy
between 70 and 77% for logistic regression and k-NN classifiers,
respectively.
Multivariate DOS–GLCM features. Table 2C presents classifica-
tion results for pairwise DOS–GLCM feature combinations. The
accuracy of optimal pairwise combinations was 77.8–79.5% for
classifying response groups. Using a logistic regression analysis, the
combination of HbO2-corþHb-hom demonstrated a %Sn of 80%,
and %Sp of 78.0%. This corresponded to an AUC of 0.815, and an
accuracy of 79.5%. In comparison to the naive Bayes model, the
optimal pairwise combination was observed using Hb-conþ
HbO2-hom, which indicated a %Sn and %Sp of 78.0% and 81.0%,
respectively. The AUC for these combined parameters was 0.773,
and the accuracy was 79.5% (Figure 5; Table 2C). Finally, using the
k-NN classifier, the best pairwise combination resulted from Hb-
cor and HbO2-con, which showed a %Sn and %Sp of 79.5% and
76.0%, respectively. The corresponding AUC was 0.802 and the
accuracy was 77.8% (Figure 5; Table 2C).
Multiple linear regression analysis and subgroup analysis. The
results of the multiple linear regression demonstrated insignificant
correlations between clinical features (age, ER/PR status, Her2
status, and tumour size) and DOS–GLCM features for this patient
cohort. However, the Hb-hom, HbO2-cor, and StO2-con features
demonstrated significant correlations to MP grading, correspond-
ing to a regression coefficient value (r) of  0.358, þ 0.375, and
 0.325, respectively (Po0.05). Results of the multiple regression
analysis are presented in Table 3.
Subgroup analysis showed that the HbO2-hom feature was the
best predictor in ERþ patients using a naive Bayes classifier
(Table 4). For patients with triple-negative tumours, the Hb-hom
was the best predictor resulting in an AUC of 0.917 (%Sn¼ 75.0%,
66.7%) using a k-NN classifier. Patients separated according to
chemotherapy groups also showed variances in optimal features;
FEC-D-treated patients classified into responders and non-
responders with a %Sn of 100.0% and Sp of 92.3% using a logistic
regression analysis for TOI-hom. Patients treated with AC-T-based
chemotherapy demonstrated an AUC of 0.896 using the HbO2-
hom feature with k-NN classification (Table 4).
DISCUSSION AND CONCLUSION
This study examined pretreatment DOS texture analysis and
machine learning techniques to statistically measure textural
heterogeneity in locally advanced breast tumours. These techniques
were used to predict breast cancer response to anthracycline- and
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Figure 1. Representative responder vs non-responder. Representative DOS parametric maps for a responder (left column) and a non-responder
(right column) are presented, and corresponding clinical contrast-enhanced magnetic resonance images of the breast. Baseline DOS images were
acquired prior to starting NAC, using a tomographic diffuse optical spectroscopy device. Parametric maps were constructed volumetrically for
analysis in order to calculate the GLCM texture features.
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taxane-based NAC. The results demonstrate for the first time that
textural heterogeneities in DOS measures of haemoglobin and
oxygen content in breast tumours predict NAC response with high
accuracy. Volumetric tumour analysis indicated that tumour-
specific ROI-data can yield highly sensitive and specific univariate
and multivariate textural markers using various classifier models.
Pretreatment DOS texture features (Hb, HbO2, HbT, St,
and StO2) were significantly different between responders and
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Figure 2. GLCM texture features for haemoglobin. Box-and-whisker plots showing significant differences in DOS textural markers for responders
and non-responders. Haemoglobin-based features at baseline demonstrated a significant difference (Po0.05) between response groups. An
unpaired student t-test was used to test the significance for normally distributed data. P-values indicated.
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Figure 3. GLCM texture features for oxygen saturation. Box-and-whisker plots showing significant differences in DOS textural markers for
responders and non-responders. Oxygen saturation parameters at baseline demonstrated a significant difference (Po0.05) between response
groups (unpaired student t-test, P-values indicated).
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non-responders. This relationship was also observed across patient
subgroups separated by ERþ , triple-negative, and chemotherapy
treatments. Receiver-operating characteristic analysis of those
features also indicated a good classification accuracy that
represents heterogeneities in blood perfusion and StO2 in breast
tumours. A previous study by Ueda et al (2012) demonstrated that
pretreatment StO2 using the mean DOS values could predict
treatment response with a %Sn and %Sp of 75.0% and 73.3%,
respectively. The study here complements those results; demon-
strating that texture-based analysis of the StO2-contrast may yield
similar statistical differences between response groups (P¼ 0.044).
Grey-level co-occurrence matrices analyses here, provided dis-
criminant features by using volumetric tumour analysis, in
addition to second-order statistical analyses that examined the
pixel-by-pixel relationships of tumour heterogeneities within the
parametric maps. Measures of spatial heterogeneity in tumour
Table 2. Results of univariate (A, B) and multivariate analysis (C) using three classification models: logistic regression analysis,
naive Bayes classifier, and k-NN
A
Significant univariate feature Classifier/Model %Sn %Sp AUC P-value Statistical power (n2)
Logistic regression 60.0 60.0 0.726
Hb-homogeneity Naive Bayes 82.0 82.0 0.799 0.030 71.8 (14)
k-NN 61.5 67.5 0.577
Logistic regression 70.0 70.0 0.756
HbO2-correlation Naive Bayes 80.0 81.0 0.778 0.024 78.9 (11)
k-NN 66.5 74.5 0.602
Logistic regression 60.0 60.0 0.657
HbT-homogeneity Naive Bayes 84.0 85.0 0.813 0.047 79.9 (11)
k-NN 74.0 47.0 0.552
Logistic regression 60.0 63.0 0.670
St-contrast Naive Bayes 79.5 82.0 0.779 0.044 73.5 (13)
k-NN 70.5 64.5 0.582
Logistic regression 70.0 63.0 0.715
StO2-contrast Naive Bayes 83.0 85.5 0.803 0.044 85.6 (enough)
k-NN 70.0 66.5 0.610
B
Univariate features Classifier/Model %Sn %Sp %Acc
HbO2-correlation Logistic regression 70.0 70.0 70.0
HbO2-homogeneity Naive Bayes 86.5 89.0 87.8
HbO2-contrast k-NN 81.0 73.0 77.0
C
Multivariate features Classifier/Model %Sn %Sp %Acc
HbO2-correlationþHb-homogeneity Logistic regression 80.0 78.0 79.5
Hb-contrastþHbO2-homogeneity Naive Bayes 78.0 81.0 79.5
Hb-correlationþHbO2-contrast k-NN 79.5 76.0 77.8
Abbreviations: %Acc¼ accuracy; AUC¼ area under curve; Hb¼deoxy-haemoglobin; HbO2¼oxy-haemoglobin; HbT¼ total haemoglobin; k-NN¼ k-nearest neighbour; Sn¼ sensitivity;
Sp¼ specificity; St¼oxygen desaturation; StO2¼ tumour oxygen saturation. Bold values indicate best classifiers. The last column in Table 2A reports the percentage of the statistical power.
The numbers inside parentheses in this column indicate the number of non-responders (n2) required in this study to achieve a statistical power of minimum 80% in case that the number of
responders (n1) is fixed at 27.
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Figure 4. Receiver-operating characteristic (ROC) curves for univariate DOS texture features. ROC curves for the best performing single DOS
texture parameter are presented.
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physiology as conducted here, could potentially provide good
characterisation of biological traits that influence tumour response
to treatment. Such features include tumour hypoxia (Hockel and
Vaupel, 2001), and haematological characteristics such as blood
flow and vascular density (Folkman, 2002). These features have
been shown to influence tumour cell proliferation and metabolism,
and therefore may also affect chemosensitivity (Folkman, 2002).
The use of such measures better reflects tumour physiology, which
is not homogeneous but rather spatially heterogeneous.
Additionally, multiparametric analysis resulted in sensitive and
specific combined markers for response classification. Logistic
regression analysis demonstrated B10% improvement in all
performance measures by using pairwise features compared to the
case of using only one single feature. However, the naive Bayes and
k-NN did not show a significant improvement. This may be related
to the small sample size used and peaking phenomena (Jain et al,
2000). Features into the pairwise models included: HbO2-cor, HbO2-
hom, Hb-cor, HbO2-con, Hb-hom, and Hb-con. Individually, those
non-texture DOS parameters were previously correlated to tumour
vasculature (Intes, 2005). Additionally, the heterogenic tumour
vasculature has been linked to mediating drug resistance; caused by
structural scaffolds that inhibit effective drug delivery (Teicher et al,
1990; Galmarini et al, 2000; Tredan et al, 2007). These include poor
vascular flow, increased interstitial fluid, and a tightly bound cellular
matrix that may constrain drugs from reaching into the tumour
stroma thereby affecting the efficacy of chemotherapies.
In comparison to other studies, texture analysis of MRI (Ahmed
et al, 2013; Golden et al, 2013; Teruel et al, 2014), ultrasound
Logistic regression analysis Naive Bayes model k-NN Model
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Figure 5. Receiver-operating characteristic (ROC) curves for multivariate DOS texture features. ROC curves for the best performing pairwise DOS
texture parameters are presented.
Table 3. Regression coefficients (r) of the multiple regression
analysis for DOS–GLCM features and corresponding
regression
DOS–GLCM
feature Comparison r F-value P-value
Hb-homogeneity Age  0.130 0.599 0.444
ER/PR status  0.087 0.267 0.608
Her2 status  0.104 0.382 0.540
Tumour size þ 0.231 1.967 0.170
Miller–Payne grade 0.358 5.137 0.030
HbO2-correlation Age  0.116 0.475 0.495
ER/PR status  0.003 0.000 0.988
Her2 status  0.109 0.418 0.522
Tumour size  0.295 3.335 0.076
Miller–Payne grade þ0.375 5.172 0.022
HbT-homogeneity Age  0.142 0.715 0.403
ER/PR status þ 0.007 0.002 0.969
Her2 status þ 0.206 1.544 0.222
Tumour size þ 0.085 0.257 0.616
Miller–Payne grade  0.233 2.015 0.165
St-contrast Age  0.231 1.972 0.169
ER/PR status þ 0.056 0.111 0.741
Her2 status þ 0.095 0.322 0.574
Tumour size  0.164 0.971 0.331
Miller–Payne grade þ 0.177 1.138 0.293
StO2-contrast Age  0.083 0.241 0.626
ER/PR status  0.074 0.190 0.665
Her2 status  0.213 1.661 0.206
Tumour size þ 0.279 2.966 0.094
Miller–Payne grade 0.325 4.140 0.050
Abbreviations: DOS¼diffuse optical spectroscopy; ER¼oestrogen receptor; GLCM¼grey-
level co-occurrence matrices; Hb¼deoxy-haemoglobin; HbO2¼oxy-haemoglobin; HbT¼
total haemoglobin; PR¼progesterone receptor; StO2¼ tumour oxygen saturation; St¼
oxygen desaturation. F-values are presented. Clinical features such as age, ER/PR status,
Her2 status, and tumour size were not significantly correlated to DOS–GLCM features in this
patient cohort. However, DOS–GLCM features such as the Hb-hom, HbO2-cor, StO2-con
were correlated to Miller–Payne pathologic response grade. Statistically significant values
are in bold.
Table 4. A subgroup analysis was completed based on ER/
PRþ and triple-negative tumours
Subgroup
Best
feature
Model %Sn %Sp AUC
ER/PRþ Hb-con Logistic
regression
76.2 66.7 0.746
HbO2-hom Naive Bayes 93.3 90.1 0.883
HbO2-con k-NN 85.8 82.5 0.851
Triple
negative
Hb-hom Logistic
regression
100.0 33.3 0.917
Hb-ene Naive Bayes 100.0 66.7 0.667
Hb-hom k-NN 75.0 66.7 0.917
FEC-D TOI-hom Logistic
regression
100.0 92.3 0.949
Hb-con Naive Bayes 60.0 81.7 0.722
Hb-hom k-NN 80.0 80.0 0.806
AC-T HbO2-cor Logistic
regression
100.0 71.4 0.837
HbO2-hom Naive Bayes 96.4 90.7 0.882
HbO2-hom k-NN 83.6 85.0 0.896
Abbreviations: AC-T¼ adriamycin, cyclophosphamide, taxol; AUC¼ area under curve;
ER¼oestrogen receptor; FEC-D¼ fluorouracil, epirubicin, cyclophosphamide, docetaxel;
Hb¼deoxy-haemoglobin; HbO2¼oxy-haemoglobin; k-NN¼ k-nearest neighbour;
PR¼progesterone receptor; Sn¼ sensitivity; Sp¼ specificity; TOI¼ tissue optical index.
Patients were also grouped according to chemotherapy type for analysis. Three
classification models were used (logistic regression, naive Bayes, and k-NN) and the best
predictive features are presented.
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spectroscopy (Sadeghi-Naini et al, 2014), and DOS (Sadeghi-Naini
et al, 2015) images have been used to assess and monitor
chemotherapy response in breast tumours during the course of
treatment. Textural analysis of pretreatment MRI-based kinetic
maps have indicated positive results for predicting chemotherapy
response in ‘triple-negative’ breast tumours (Golden et al, 2013).
Those results also strongly suggest that pretreatment tumour
heterogeneity can influence drug resistance (Golden et al, 2013).
Other similar studies have examined texture features of dynamic
contrast-enhanced MRI images to predict NAC response (Ahmed
et al, 2013; Teruel et al, 2014). Results have indicated significant
differences in GLCM texture features between responders and
non-responders at pretreatment (Ahmed et al, 2013) and have
reported an increase in textural heterogeneity caused by necrotic
tumour areas (Ahmed et al, 2013). Those studies demonstrated
comparable frameworks to the present study. Specifically, that
heterogeneous tumour features caused by pathophysiology, and
initial biochemical composition might play an important role in
chemoresistance.
In terms of novelty, the results indicate that selecting volumetric
tumour-based ROIs may improve the method for DOS texture
analysis to predict NAC response. Additionally, we compared the
performance of several classification methods and found that using
naive Bayes classifier demonstrated high accuracy in predicting
chemotherapy treatment response. The preliminary work in this
study highlights an important phase in the ‘imaging biomarker
roadmap’ outlined by Cancer Research UK (CRUK) and the
European Organisation for Research and Treatment of Cancer
(EORTC) (O’Connor et al, 2017). Diffuse optical spectroscopy-
based biomarkers have surpassed the initial translational gap
outlined within this roadmap; specifically, as a useful tool in
medical research (O’Connor et al, 2017). Several works by Cerussi
et al (2007), Tromberg et al (2005), and Roblyer et al (2011) have
made significant contributions towards crossing the second
translational gap; particularly, for DOS to be used as a clinical
decision-making tool (Tromberg et al, 2005; Cerussi et al, 2007;
Roblyer et al, 2011). In order for DOS-based imaging biomarkers
to be considered clinically useful in personalised medicine, further
research is required to build standard operating procedures for
DOS imaging biomarkers for treatment response with validated
cutoff points, removing bias, setting-up standard practices for
image processing techniques and ensuring comparability to
pathology (O’Connor et al, 2017). The work here builds on
determining optimal techniques for where DOS could be used as a
predictive or prognostic marker. Using DOS imaging biomarkers
to guide cancer therapies can potentially reduce costs to the health-
care system by mitigating ineffective treatments. Therefore, DOS
imaging used for routine cancer care would necessitate a cost-
effectiveness analysis to quantify the added value to the health-care
system (O’Connor et al, 2017).
Limitations in this study include a limited sample size; although
the patient cohort size has been improved compared to our
previous study (Sadeghi-Naini et al, 2015). The statistical test of
significance was performed with a relatively small sample size in
each responding group (n1¼ 27 and n2¼ 10) (Siegel and Castellan,
1988; de Winter, 2013). In order to evaluate the reliability of the
performed tests, the statistical power (SP) was calculated using
PASS14 (NCSS, LLC. Kaysville, Utah, USA). The results obtained
are reported in the rightmost column in Table 2A. As can be seen
from these results, the SP for the statistically significant parameters
varied between 71.8 and 85.6%. This is one of the limitations of this
study, as a threshold of 70% has to be considered for the SP instead
of a commonly used threshold of 80%. By fixing the number of
responders (n1¼ 27), we have also estimated the number of non-
responders (n2) required to achieve a minimum SP of 80%, which
are reported inside parentheses in the rightmost column in
Table 2A. As can be seen from this analysis, at most four additional
non-responders are needed to achieve an 80% SP. This change
would permit stronger conclusions to be drawn from this study.
We note that this study used binary response classifications
(R vs NR) and that the ratio of response groups in this cohort is
biased towards the responders (complete pathologic and partial
responders were grouped into one category). This was due to the
chosen MP cutoff point.
Within the framework of the CRUK and EORTC imaging
biomarker discovery roadmap, future work would require an
increase in the number of patients to strengthen the statistical
conclusions. This would subsequently allow classifying patients
into multiple response categories (MP 1–5). Increasing the number
of patients would also permit testing for repeatability, reproduci-
bility, and would increase precision via multicentre trials
(O’Connor et al, 2016). Baseline DOS imaging biomarkers could
also be used to predict long-term survival data for patients. Taken
together, these early results suggest that there is an opportunity for
DOS–GLCM analysis to improve analysis and classification of
tumour response prior to the start of NAC in breast patients.
In conclusion, this study investigated baseline DOS functional
maps using GLCM texture analysis to classify patient response to
NAC. In comparison to our previous study where we analysed
DOS textures of the whole breast; here, we analysed the DOS
texture features within the tumour region only (Sadeghi-Naini
et al, 2015). The results indicated that such indices can differentiate
between response groups prior to the start of treatment with high
%Sn and %Sp. Although further studies are required, this first
report demonstrates promising potential for DOS-based textural
parameters to evaluate baseline tumour vascular heterogeneity, and
subsequently as markers for response to chemotherapy. The use of
these markers may help guide treatments to personalise patient-
care plans by potentially predicting chemoresponse. Ultimately if
used to guide therapy, DOS-based texture analysis may help
improve breast cancer therapeutics, and may potentially improve
overall disease-free survival.
ACKNOWLEDGEMENTS
This project was funded by the Terry Fox Research Institute,
Canada. We thank Professor Heidi Probst from Sheffield Hallam
University (Sheffield, United Kingdom).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Ahmed A, Gibbs P, Pickles M, Turnbull L (2013) Texture analysis in
assessment and prediction of chemotherapy response in breast cancer.
J Magn Reson Imaging 38: 89–101.
Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, Rosenman J,
Ollila DW, Graham 2nd M (2002) Long-term outcome of neoadjuvant
therapy for locally advanced breast carcinoma: effective clinical
downstaging allows breast preservation and predicts outstanding local
control and survival. Ann Surg 236: 295–302discussion 302-3.
Castellano G, Bonilha L, Li LM, Cendes F (2004) Texture analysis of medical
images. Clin Radiol 59: 1061–1069.
Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, Tromberg BJ
(2007) Predicting response to breast cancer neoadjuvant chemo-
therapy using diffuse optical spectroscopy. Proc Natl Acad Sci USA 104:
4014–4019.
Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ (2006) In vivo
absorption, scattering, and physiologic properties of 58 malignant breast
Predicting chemotherapy response using DOS texture BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.97 9
tumors determined by broadband diffuse optical spectroscopy. J Biomed
Opt 11: 044005.
Cerussi AE, Tanamai VW, Hsiang D, Butler J, Mehta RS, Tromberg BJ (2011)
Diffuse optical spectroscopic imaging correlates with final pathological
response in breast cancer neoadjuvant chemotherapy. Philos Trans A
Math Phys Eng Sci 369: 4512–4530.
Chen W, Giger ML, Li H, Bick U, Newstead GM (2007) Volumetric texture
analysis of breast lesions on contrast-enhanced magnetic resonance
images. Magn Reson Med 58: 562–571.
Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, COOK GJ (2013)
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by
texture analysis. Eur J Nucl Med Mol Imaging 40: 133–140.
de Winter JCF (2013) Using the Student’s t-test with extremely small sample
sizes. Pract Assess Res Eval 18: 1–10.
Desantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R,
Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics,
2014. CA Cancer J Clin 64: 252–271.
Duda RO, Hart PE, Stork DG (2001) Pattern Classification. Wiley: New York.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, SHANKAR L,
DODD L, KAPLAN R, Lacombe D, Verweij J (2009) New response
evaluation criteria in solid tumours: revised RECIST guideline (version
1.1). Eur J Cancer 45: 228–247.
Evans A, Armstrong S, Whelehan P, Thomson K, Rauchhaus P, Purdie C,
Jordan L, Jones L, Thompson A, Vinnicombe S (2013) Can shear-wave
elastography predict response to neoadjuvant chemotherapy in women
with invasive breast cancer? Br J Cancer 109: 2798–2802.
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin
Oncol 29: 15–18.
Galmarini FC, Galmarini CM, Sarchi MI, Abulafia J, Galmarini D (2000)
Heterogeneous distribution of tumor blood supply affects the response to
chemotherapy in patients with head and neck cancer. Microcirculation 7:
405–410.
Gibbs P, Turnbull LW (2003) Textural analysis of contrast-enhanced MR
images of the breast. Magn Reson Med 50: 92–98.
Giordano SH (2003) Update on locally advanced breast cancer. Oncologist 8:
521–530.
Golden DI, Lipson JA, Telli ML, Ford JM, Rubin DL (2013) Dynamic
contrast-enhanced MRI-based biomarkers of therapeutic response
in triple-negative breast cancer. J Am Med Inform Assoc 20: 1059–1066.
Gupta R, Undrill PE (1995) The use of texture analysis to delineate suspicious
masses in mammography. Phys Med Biol 40: 835–855.
Haralick RM, Shanmugam K, Dinstein I (1973) Textural features for image
classification. IEEE Trans Syst Man Cybern 3: 610–621.
Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical,
biologic, and molecular aspects. J Natl Cancer Inst 93: 266–276.
Intes X (2005) Time-domain optical mammography SoftScan: initial results.
Acad Radiol 12: 934–947.
Jain AK, Duin RPW, Mao J (2000) Statistical pattern recognition: a review.
IEEE Trans Pattern Anal Mach Intell 22: 4–37.
Jakubowski DB, Cerussi AE, Bevilacqua F, Shah N, Hsiang D, Butler J,
Tromberg BJ (2004) Monitoring neoadjuvant chemotherapy in breast
cancer using quantitative diffuse optical spectroscopy: a case study.
J Biomed Opt 9: 230–238.
Jiang S, Pogue BW, Kaufman PA, Gui J, Jermyn M, Frazee TE, Poplack SP,
Diflorio-Alexander R, Wells WA, Paulsen KD (2014) Predicting breast tumor
response to neoadjuvant chemotherapy with diffuse optical spectroscopic
tomography prior to treatment. Clin Cancer Res 20: 6006–6015.
Lee MC, Newman LA (2007) Management of patients with locally advanced
breast cancer. Surg Clin North Am 87: 379–398ix.
Lerski RA, Straughan K, Schad LR, Boyce D, Bluml S, Zuna I (1993) MR
image texture analysis–an approach to tissue characterization.Magn Reson
Imaging 11: 873–887.
Li H, Giger ML, Olopade OI, Margolis A, Lan L, Chinander MR (2005)
Computerized texture analysis of mammographic parenchymal patterns of
digitized mammograms. Acad Radiol 12: 863–873.
Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF (2009)
Neoadjuvant chemotherapy for locally advanced breast cancer: a review of
the literature and future directions. Eur J Surg Oncol 35: 113–122.
Mourant JR, Canpolat M, Brocker C, Esponda-Ramos O, Johnson TM,
Matanock A, Stetter K, Freyer JP (2000) Light scattering from cells: the
contribution of the nucleus and the effects of proliferative status. J Biomed
Opt 5: 131–137.
National Institute For Health And Clinical Excellence (NICE) (2009) Early
and Locally Advanced Breast Cancer: Diagnosis and Treatment. NICE:
Cardiff, UK.
O’Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ,
Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL,
Clarke LP, Collette S, Cook GJ, Desouza NM, Dickson JC, Dive C,
Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V,
Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS,
Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM,
Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS,
Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B,
Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC,
Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA,
Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM,
Van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P,
Yankeelov TE, Brindle KM, Mcshane LM, Jackson A, Waterton JC (2017)
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 14:
169–186.
Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I,
Schofield A, Heys SD (2003) A new histological grading system to assess
response of breast cancers to primary chemotherapy: prognostic
significance and survival. Breast 12: 320–327.
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C,
Macgrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM,
Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J,
Yang W, Symmans WF, Residual Disease Characterization Working
Group Of The Breast International Group-North American Breast Cancer
Group, C (2015) Standardization of pathologic evaluation and reporting of
postneoadjuvant specimens in clinical trials of breast cancer:
recommendations from an International Working Group. Mod Pathol 28:
1185–1201.
Roblyer D, Ueda S, Cerussi A, Tanamai W, Durkin A, Mehta R, Hsiang D,
Butler JA, Mclaren C, Chen WP, Tromberg B (2011) Optical imaging of
breast cancer oxyhemoglobin flare correlates with neoadjuvant
chemotherapy response one day after starting treatment. Proc Natl Acad
Sci USA 108: 14626–14631.
Sadeghi-Naini A, Sannachi L, Pritchard K, Trudeau M, Gandhi S,
Wright FC, Zubovits J, Yaffe MJ, Kolios MC, Czarnota GJ (2014)
Early prediction of therapy responses and outcomes in breast cancer
patients using quantitative ultrasound spectral texture. Oncotarget 5:
3497–3511.
Sadeghi-Naini A, Vorauer E, Chin L, Falou O, Tran WT, Wright FC,
Gandhi S, Yaffe MJ, Czarnota GJ (2015) Early detection of chemotherapy-
refractory patients by monitoring textural alterations in diffuse optical
spectroscopic images. Med Phys 42: 6130–6146.
Schaafsma BE, Van De Giessen M, Charehbili A, Smit VT, Kroep JR,
Lelieveldt BP, Liefers GJ, Chan A, Lowik CW, Dijkstra J, Van De Velde CJ,
Wasser MN, Vahrmeijer AL (2015) Optical mammography using diffuse
optical spectroscopy for monitoring tumor response to neoadjuvant
chemotherapy in women with locally advanced breast cancer. Clin Cancer
Res 21: 577–584.
Siegel S, Castellan NJ (1988) Nonparametric Statistics for the Behavioral
Sciences. McGraw-Hill: New York.
Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW,
Frei 3rd E (1990) Tumor resistance to alkylating agents conferred by
mechanisms operative only in vivo. Science 247: 1457–1461.
Teruel JR, Heldahl MG, Goa PE, Pickles M, Lundgren S, Bathen TF, Gibbs P
(2014) Dynamic contrast-enhanced MRI texture analysis for pretreatment
prediction of clinical and pathological response to neoadjuvant
chemotherapy in patients with locally advanced breast cancer. NMR
Biomed 27: 887–896.
Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance
and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441–1454.
Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, Butler J,
Mehta R (2005) Imaging in breast cancer: diffuse optics in breast cancer:
detecting tumors in pre-menopausal women and monitoring neoadjuvant
chemotherapy. Breast Cancer Res 7: 279–285.
Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y, Xu S,
O’Sullivan TD, Hsiang D, Mehta R, Butler J, Tromberg BJ (2012) Baseline
tumor oxygen saturation correlates with a pathologic complete response in
breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res
72: 4318–4328.
BRITISH JOURNAL OF CANCER Predicting chemotherapy response using DOS texture
10 www.bjcancer.com |DOI:10.1038/bjc.2017.97
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H,
Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C,
Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S
(2012) Definition and impact of pathologic complete response on
prognosis after neoadjuvant chemotherapy in various intrinsic breast
cancer subtypes. J Clin Oncol 30: 1796–1804.
Whitman GJ, Strom EA (2009) Workup and staging of locally advanced breast
cancer. Semin Radiat Oncol 19: 211–221.
Xu RX, Povoski SP (2007) Diffuse optical imaging and spectroscopy for
cancer. Expert Rev Med Devices 4: 83–95.
Yang X, Tridandapani S, Beitler JJ, Yu DS, Yoshida EJ, Curran WJ, Liu T
(2012) Ultrasound GLCM texture analysis of radiation-induced parotid-
gland injury in head-and-neck cancer radiotherapy: an in vivo study of late
toxicity. Med Phys 39: 5732–5739.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Predicting chemotherapy response using DOS texture BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.97 11
